NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Sidoti Small-Cap Conference being held virtually June 12-13, 2024.
Presentation Details
Date: Wednesday, June 12, 2024
Time: 4:00 p.m. Eastern Time
Registration/Webcast Link
For more information about the conference, or to schedule a one-on-one meeting with the INBS management team, please contact your Sidoti representative or email KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for various indications, ranging from immunological conditions to communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Company Contact:
Intelligent Bio Solutions Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.82 |
Daily Change: | -0.03 -1.62 |
Daily Volume: | 188,033 |
Market Cap: | US$5.680M |
September 27, 2024 September 25, 2024 September 19, 2024 September 09, 2024 September 05, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB